Advertisement

Schleimhauttoxizität und Motilitätsstörungen

  • J. T. Hartmann
  • H.-P. Lipp
  • M. Björnsgard
  • C. Bokemeyer
Chapter
  • 21 Downloads

Zusammenfassung

Mundschleimhautulzerationen stellen eine häufige und nicht selten dosislimitierende Toxizität insbesondere nach hochdosierter Chemotherapie dar. Sie treten meist innerhalb der ersten zwei Wochen nach Zytostatikagabe auf, sind oft sehr schmerzhaft und können die orale Nahrungsaufnahme erheblich erschweren. Darüber hinaus begünstigen schwere Mukositiden den Eintritt von Mikroorganismen in den systemischen Kreislauf, da die Schleimhäute ihre natürliche Barrierefunktion nicht mehr angemessen erfüllen können.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu 4.1

  1. Carl W (1995) Oral complications of local and systemic cancer treatment. Curr Opin Oncol 7: 320–324PubMedCrossRefGoogle Scholar
  2. Chi KH, Chen CH, Chan WK et al. (1995) Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 13: 2620–8PubMedGoogle Scholar
  3. Dumontet C, Sonnet A, Bastion Y et al. (1994) Prevention of high-dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 14: 492–494PubMedCrossRefGoogle Scholar
  4. Epstein JB, Wong FLW (1994) The efficacy of sucralfate in the prevention of oral mucositis due to radiation therapy. Int J Radiat Oncol Biol Phys 28: 693–698PubMedCrossRefGoogle Scholar
  5. Fidler P, Loprinzi CL, O’Fallon JR et al. (1996) Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 77: 522–525PubMedCrossRefGoogle Scholar
  6. Helmstädter A (1991) Chemotherapiebedingte Mundschleimhautläsionen — Prophylaxe und Therapie mit Lösungen zur lokalen Anwendung. Krankenhauspharmazie 12: 99–103Google Scholar
  7. Henriksson R, Franzen L, Edbom C, Littbrand B (1995) Sucralfate: prophylaxis of mucosal damage during cancer therapy. Scand J Gastroenterol Suppl 210: 45–47PubMedCrossRefGoogle Scholar
  8. Hoekman K, Vermorken JB (1996) Incidence and prevention of nonhaematological toxicity of high-dose chemotherapy. Ann Med 28: 175–182PubMedCrossRefGoogle Scholar
  9. Labar B, Mrsic M, Pavletic Z et al. (1993) Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 11: 379–382PubMedGoogle Scholar
  10. Mueller BA, Mülheim ET, Farrington EA, Brusko C, Wiser TH (1995) Mucositis management practices for hospitalized patients: national survey results. J Pain Symptom Manage 10: 510–520PubMedCrossRefGoogle Scholar
  11. Skubitz KM, Anderson PM (1996) Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med 127: 223–228PubMedCrossRefGoogle Scholar
  12. Sonis S, Clark J (1991) Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology (Huntington) 5: 11–18Google Scholar
  13. Sonis ST, Costello KA (1995) A database for mucositis induced by cancer chemotherapy. Eur J Cancer B Oral Oncol 31 B: 258–60CrossRefGoogle Scholar
  14. Verdi CJ (1993) Cancer Therapy and Oral Mucositis. Drug Safety 9: 185–195PubMedCrossRefGoogle Scholar

Literatur zu 4.2

  1. Balson R, Gibson PR (1995) Lower gastrointestinal tract: constipation. Med J Austr 162: 155–157Google Scholar
  2. Baillie-Johnson HR (1996) Octreotide in the management of treatment-related diarrhoea. Anticancer Drugs 7 (Suppl1): 11–15PubMedCrossRefGoogle Scholar
  3. Cascinu S (1995) Management of diarrhea induced by tumors or cancer therapy. Curr Opin Oncol 7: 325–329PubMedCrossRefGoogle Scholar
  4. Crouch MA, Restino MS, Cruz JM, Perry JJ, Hurd DD (1996) Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother, 30: 331–336PubMedGoogle Scholar
  5. Di Pesaro O (1995) Management of diarrhea induced by tumors or cancer therapy. Curr Opin Oncol 7: 325–329CrossRefGoogle Scholar
  6. Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61: 369–372PubMedCrossRefGoogle Scholar
  7. Geller RB, Gilmore CE, Dix SP et al (1995) Randomized trial of loperamide vs. dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 50: 167–172PubMedCrossRefGoogle Scholar
  8. Peters M, Gerken G (1994) Die akute und chronische Diarrhö — Ein differentialdiagnostisches und therapeutiches Problem. Med Monatsschr Pharm 17: 358–365PubMedGoogle Scholar
  9. Rougier P, Bugat R (1996) CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23 (Suppl 3): 34–41PubMedGoogle Scholar
  10. Rougier P, Bugat R, Douillard JY et al. (1997) Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251–260PubMedGoogle Scholar
  11. Schöffski P (1996) Prävention und Therapie der Obstipation bei Tumorpatienten. In: Schmoll H-J, Höffken K, Possinger K (Hrsg) Kompendium der internistischen Onkologie. Springer, Berlin Heidelberg New York Tokio, S 1188–1199Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • J. T. Hartmann
  • H.-P. Lipp
  • M. Björnsgard
  • C. Bokemeyer

There are no affiliations available

Personalised recommendations